By. Stuart McIntosh, MDDate. November 03, 2023Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology.…
Browsing: Elacestrant
Virginia Kaklamani, MD – UT Health San Antonio discusses Elacestrant (ORSERDU), an oral endocrine therapy, has been approved by the…
Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer…
iFrame is not supported! Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So…
Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer…
iFrame is not supported! Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial…
Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial In ER-positive, HER2-negative Metastatic…